Definitive Healthcare Q1 2025 slides: revenue declines 7% YoY, beats guidance

Introduction & Market Context

Definitive Healthcare Corp (NASDAQ:DH) released its first quarter 2025 earnings presentation on May 8, 2025, revealing results that exceeded guidance despite ongoing revenue challenges. The healthcare data and analytics provider continues to navigate a difficult macroeconomic environment, with its stock trading near 52-week lows at $2.81 per share, reflecting persistent investor concerns following a significant sell-off after disappointing Q4 2024 results.

Quarterly Performance Highlights

Definitive Healthcare reported Q1 2025 revenue of $59.2 million, representing a 7% year-over-year decline but exceeding the high end of the company’s guidance range of $55.5-57.0 million. The company maintained 512 enterprise customers (defined as those with more than $100,000 in annual recurring revenue), though this marked a decrease of 29 customers year-over-year.

As shown in the following performance highlights slide, the company’s executives emphasized operational efficiency and new customer acquisition despite market headwinds:

CEO Kevin Coop highlighted "solid new logo momentum across markets" while CFO Rick Booth noted the company remains "focused on what we can control" as they continue efforts to operate more efficiently while delivering innovation for clients.

Detailed Financial Analysis

The company’s Q1 2025 financial results showed margin compression alongside revenue declines. Adjusted EBITDA reached $14.7 million, representing a 25% margin—a 670 basis point contraction from the prior year’s 32% margin. However, this still exceeded the company’s guidance of $10.5-11.5 million.

The detailed profit and loss statement reveals the financial impact of the revenue decline:

Notably, subscription revenue continues to dominate the company’s business model at 97% of total revenue. Adjusted gross profit declined 11% year-over-year to $47.1 million, with adjusted gross margin contracting 411 basis points to 80%.

Despite these challenges, Definitive Healthcare demonstrated strong cash flow performance. Cash flow from operations increased 57% year-over-year to $26.1 million, though unlevered free cash flow declined 19% to $22.9 million, partly due to increased capital expenditures.

The company’s balance sheet shows significant debt reduction and healthy cash reserves:

Total (EPA:TTEF) debt outstanding decreased 32% year-over-year to $172.8 million, with the company refinancing its debt in January 2025 and paying down $69 million during the process. Cash, cash equivalents, and short-term investments totaled $200.7 million as of March 31, 2025, resulting in a net leverage ratio of less than zero.

A significant financial event during the quarter was a $176.5 million goodwill impairment charge, which contributed to a GAAP net loss of $155.1 million. This non-cash charge reflects challenges with previous acquisitions and current market valuations.

Forward-Looking Statements

Definitive Healthcare raised the low end of its full-year 2025 revenue guidance from $230 million to $234 million, citing solid Q1 results. The company now projects full-year revenue between $234.0-240.0 million, representing a 5-7% year-over-year decline.

For the second quarter of 2025, the company expects:

The guidance suggests continued revenue challenges but gradual stabilization throughout the year. Management remains committed to maintaining profitability, projecting adjusted EBITDA margins between 26-28% for the full year.

The comparison between actual Q1 results and previous guidance demonstrates the company’s ability to outperform its conservative projections:

Revenue outperformance, combined with prudent spending constraints and some timing benefits, drove adjusted EBITDA significantly above expectations at $14.7 million versus guidance of $10.5-11.5 million.

Market Response & Investor Sentiment

Despite outperforming guidance, Definitive Healthcare continues to face skepticism from investors. The stock trades near its 52-week low following a substantial drop after Q4 2024 results, when the company missed EPS expectations by a wide margin. Current trading at $2.81 represents a slight recovery from the 52-week low of $2.15 but remains far below the 52-week high of $6.27.

The company’s share repurchase program remains active, with $77 million in authorization remaining. As of March 31, 2025, a total of 10.4 million Class A shares had been repurchased for $43.3 million under the company’s buyback programs, demonstrating management’s confidence in the company’s long-term value despite current challenges.

While Definitive Healthcare faces continued headwinds, its Q1 2025 results suggest the company may be stabilizing its business with improved operational efficiency and cash flow management, even as revenue growth remains elusive in the current market environment.

Full presentation:

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.